← Back to Clinical Trials
Recruiting Phase 3 NCT02829190

NCT02829190 Feasibility Study of Phase-contrast MRI for Flow in the External Carotid Branches Arteries

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT02829190
Status Recruiting
Phase Phase 3
Sponsor Centre Hospitalier Universitaire, Amiens
Condition Carotid Artery, External
Study Type INTERVENTIONAL
Enrollment 80 participants
Start Date 2014-01-06
Primary Completion 2027-12

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age 70 Years
Study Type INTERVENTIONAL
Interventions
Magnetic Resonance Imaging (MRI),

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

Phase 3 trials are large pivotal studies comparing the treatment to current standard of care or placebo. Your participation directly contributes to the evidence needed for regulatory approval.

This trial targets 80 participants in total. It began in 2014-01-06 with a primary completion date of 2027-12.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

The phase-contrast MRI offers the advantage to combine precisely vascular flow measurements data with morphological images. Even if the anatomy of the external carotid artery is well known, data obtained through Phase contrast MRI could permit to progress in several fields of cranio-maxillofacial surgery as for example arteriovenous malformations,radionecrosis, head and neck micro-reconstructive surgery. The aim of this study is to establish and develop Phase-contrast MRI sequences for vascular flow characterization branches of the external carotid artery in healthy patients and in pathological cases.

Eligibility Criteria

Inclusion Criteria: * group 1 : healthy volunteer * group 2 : X-Ray treatment antecedent (at least 50 grays and older than one year) * group 3 : antecedent of embolization of branches of external carotid artery * group 4 : antecedent of muscular free flap surgery (older than one month) * free and informed consent Exclusion Criteria: * group 1 : facial pathology, antecedent of facial injury, antecedent of X-Ray treatment in head and neck localisation, antecedent of head and neck cancer * group 2 : antecedent of surgery for head and neck cancer or for vascular disease * group 3 : antecedent of surgery for head and neck cancer or for vascular disease ; antecedent of X-Ray treatment. * group 4 : antecedent of surgery for head and neck cancer or for vascular disease ; antecedent of X-Ray treatment or embolization * patient with guardianship or trusteeship * MRI cons-indications * pregnancy and lactation

Contact & Investigator

Central Contact

Stéphanie DAKPE, MD

✉ dakpe.stephanie@chu-amiens.fr

📞 03 22 08 90 50

Principal Investigator

Bernard DEVAUCHELLE, MD, phD

PRINCIPAL INVESTIGATOR

Amiens University Hospital

Frequently Asked Questions

Who can join the NCT02829190 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, up to 70 Years, studying Carotid Artery, External. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

What phase is the NCT02829190 trial and what does that mean for participants?

Phase 3 trials are large-scale studies comparing the new treatment to existing standards of care or a placebo. They provide the evidence needed for regulatory approval. This trial targets 80 participants.

Is NCT02829190 currently recruiting?

Yes, NCT02829190 is actively recruiting participants. Contact the research team at dakpe.stephanie@chu-amiens.fr for enrollment information.

Where is the NCT02829190 trial being conducted?

This trial is being conducted at Amiens, France.

Who is sponsoring the NCT02829190 clinical trial?

NCT02829190 is sponsored by Centre Hospitalier Universitaire, Amiens. The principal investigator is Bernard DEVAUCHELLE, MD, phD at Amiens University Hospital. The trial plans to enroll 80 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology